Journal of Cytokine Biology
Open Access

Cytokines; Gene expression; Epigenetic modifications; JAK-STAT pathway; MAPK pathway; DNA methylation; Histone modifications; Non-coding RNAs; Autoimmune diseases; Cancer; Chronic inflammatory diseases; Targeted therapies; JAK inhibitors; Cytokine antagonists; Epigenetic drugs

Introduction

Cytokines, small proteins crucial for cell signaling, play a pivotal role in the immune response. They influence various cellular processes, including gene expression and epigenetic modifications, which can have profound implications for disease progression and therapy. Understanding how cytokines induce changes at the genetic and epigenetic levels offers insights into disease mechanisms and potential therapeutic strategies.

Cytokine-induced gene expression

Cytokines exert their effects by binding to specific receptors on the surface of target cells, initiating signaling cascades that result in the activation of transcription factors. These transcription factors then regulate the expression of genes involved in immune responses, cell proliferation, differentiation, and apoptosis [1].

Signal transduction pathways

JAK-STAT pathway: One of the primary pathways through which cytokines influence gene expression is the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway. Upon cytokine binding, JAKs phosphorylate STAT proteins, which dimerize and translocate to the nucleus to initiate gene transcription.

MAPK pathway: The mitogen-activated protein kinase (MAPK) pathway is another critical signaling route. Cytokine binding activates MAPKs, which then activate transcription factors like AP-1 that regulate gene expression.

Transcriptional regulation

Immediate early genes: Cytokines can rapidly induce the expression of immediate early genes (IEGs) that encode transcription factors, cytokines, and other proteins involved in the immune response.

Secondary response genes: These are activated by the proteins encoded by IEGs and are involved in more sustained cellular responses, such as proliferation and differentiation [2].

Epigenetic modifications induced by cytokines

Epigenetic modifications refer to heritable changes in gene expression without alterations in the DNA sequence. Cytokines can induce various epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA expression.

DNA methylation

Gene silencing: Cytokines can influence DNA methylation patterns, leading to the silencing of specific genes. For example, pro-inflammatory cytokines like TNF-α can induce hypermethylation of tumor suppressor genes, contributing to oncogenesis.

Gene activation: Conversely, cytokines can also lead to DNA demethylation, resulting in the activation of genes involved in immune responses [3].

Histone modifications

Histone acetylation: Cytokines can regulate histone acetylation, a modification associated with gene activation. For instance, IL-6 can induce histone acetylation at the promoters of inflammatory genes, enhancing their expression.

Histone methylation: Methylation of histones can either activate or repress gene expression depending on the specific residues modified. Cytokines such as IFN-γ can induce histone methylation patterns that promote the expression of antiviral genes.

Non-coding RNAs

MicroRNAs (miRNAs): Cytokines can modulate the expression of miRNAs, small non-coding RNAs that regulate gene expression post-transcriptionally. For example, IL-1β can induce the expression of miR-155, which plays a role in inflammatory responses.

Long non-coding RNAs (lncRNAs): These larger non-coding RNAs can also be regulated by cytokines and are involved in various cellular processes, including chromatin remodeling and gene expression regulation.

Implications for disease

The cytokine-induced changes in gene expression and epigenetic modifications are central to the pathogenesis of various diseases, including autoimmune disorders, cancers, and chronic inflammatory conditions.

Autoimmune diseases

Rheumatoid arthritis (RA): Pro-inflammatory cytokines like TNF-α and IL-6 induce gene expression and epigenetic changes that contribute to the chronic inflammation and joint destruction seen in RA.

Systemic lupus erythematosus (SLE): Aberrant cytokine signaling can lead to epigenetic modifications that result in the dysregulation of immune tolerance and autoimmunity in SLE [4].

Cancer

Tumor microenvironment: Cytokines within the tumor microenvironment can induce epigenetic modifications that promote tumor growth and metastasis. For instance, IL-6 and IL-8 can lead to the activation of oncogenes and the silencing of tumor suppressor genes.

Therapeutic resistance: Cytokine-induced epigenetic changes can also contribute to resistance to cancer therapies. Understanding these mechanisms can help in developing strategies to overcome therapeutic resistance.

Chronic inflammatory diseases

Inflammatory bowel disease (IBD): Cytokines like TNF-α and IL-1β play a significant role in the inflammation and tissue damage seen in IBD through the regulation of gene expression and epigenetic modifications.

Asthma: Cytokine signaling in asthma can lead to epigenetic changes that result in airway hyperresponsiveness and inflammation [5].

Therapeutic implications

Understanding cytokine-induced gene expression and epigenetic modifications opens new avenues for therapeutic interventions.

Targeting cytokine signaling

JAK inhibitors: These inhibitors can block cytokine signaling pathways, reducing inflammation and altering gene expression patterns in diseases like RA and psoriasis.

Cytokine antagonists: Therapeutics that neutralize specific cytokines, such as TNF inhibitors, can modulate gene expression and epigenetic changes to treat autoimmune and inflammatory diseases.

Epigenetic therapies

DNA methylation inhibitors: Drugs that inhibit DNA methylation, such as azacitidine, can reactivate silenced tumor suppressor genes in cancer therapy.

Histone deacetylase inhibitors (HDACi): These inhibitors can alter histone acetylation patterns, leading to the reactivation of silenced genes and the suppression of oncogenic pathways.

RNA-based therapies

miRNA mimics and inhibitors: Modulating the levels of specific miRNAs can influence gene expression patterns and provide therapeutic benefits in diseases like cancer and autoimmune disorders.

Antisense oligonucleotides: These molecules can target and degrade specific mRNAs, altering gene expression patterns driven by cytokine signaling [6].

Materials and Methods

1. Cytokine stimulation of cell lines

Cell culture:

Cell lines: Use human cell lines such as HeLa (cervical cancer), THP-1 (monocytic leukemia), and primary human peripheral blood mononuclear cells (PBMCs).

Culture conditions: Maintain cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37°C in a 5% CO2 atmosphere.

Cytokine treatment:

Cytokines: Utilize cytokines such as TNF-α, IL-6, IL-1β, and IFN-γ.

Concentrations: Treat cells with cytokines at concentrations ranging from 10 to 100 ng/mL.

Time points: Harvest cells at various time points post-treatment (e.g., 0, 1, 3, 6, 12, and 24 hours) to assess time-dependent effects [7].

2. Gene expression analysis

RNA extraction:

Method: Use TRIzol reagent or an equivalent for total RNA extraction from treated and control cells.

Quality control: Assess RNA quality and quantity using a NanoDrop spectrophotometer and agarose gel electrophoresis.

Reverse transcription and qPCR:

cDNA synthesis: Perform reverse transcription using a high-capacity cDNA reverse transcription kit.

Quantitative PCR (qPCR): Utilize SYBR Green or TaqMan assays to quantify gene expression. Use specific primers for target genes (e.g., STAT1, IL6, TNFA) and housekeeping genes (e.g., GAPDH, ACTB).

Data analysis: Normalize expression levels to housekeeping genes and analyze relative expression using the ΔΔCt method.

3. Epigenetic modifications analysis

DNA methylation:

Bisulfite conversion: Perform bisulfite conversion of genomic DNA using a bisulfite conversion kit.

Methylation-specific PCR (MSP): Design primers specific for methylated and unmethylated DNA regions of target genes.

Sequencing: Use pyrosequencing or next-generation sequencing to quantify methylation levels [8].

Histone modifications:

Chromatin immunoprecipitation (ChIP):

Protocol: Crosslink proteins to DNA using formaldehyde, shear chromatin, and immunoprecipitate with antibodies specific to histone modifications (e.g., H3K27ac, H3K4me3).

Antibodies: Use validated antibodies for histone modifications.

ChIP-qPCR: Quantify enriched DNA regions by qPCR with primers specific for gene promoters or enhancers.

Non-coding RNAs:

miRNA extraction: Isolate miRNAs using a miRNA isolation kit.

qPCR for miRNAs: Perform reverse transcription and qPCR for specific miRNAs using miRNA-specific primers.

lncRNA analysis: Extract total RNA, including lncRNAs, and perform qPCR for specific lncRNAs [9].

4. Data analysis

Statistical analysis:

Software: Use statistical software such as GraphPad Prism or R for data analysis.

Tests: Perform statistical tests such as t-tests or ANOVA to determine the significance of differences between treated and control groups.

Bioinformatics: Use bioinformatics tools to analyze sequencing data, identify differentially expressed genes, and annotate epigenetic modifications.

Reproducibility:

Biological replicates: Perform experiments in triplicate to ensure reproducibility.

Technical replicates: Include technical replicates for qPCR and ChIP-qPCR to confirm accuracy [10].

5. Validation and functional assays

Gene knockdown/overexpression:

siRNA/CRISPR-Cas9: Use siRNA or CRISPR-Cas9 to knock down or knock out target genes and assess the impact on cytokine-induced responses.

Overexpression: Transfect cells with plasmids encoding target genes to study the effects of overexpression.

Functional assays:

Proliferation assays: Measure cell proliferation using assays such as MTT or BrdU incorporation.

Apoptosis assays: Assess apoptosis using flow cytometry with annexin V/propidium iodide staining.

Cytokine production: Quantify cytokine levels in culture supernatants using ELISA.

Discussion

The interplay between cytokine signaling and gene expression regulation is critical in understanding the molecular basis of immune responses and their implications for various diseases. Cytokines, by binding to specific cell surface receptors, activate signaling pathways such as JAK-STAT and MAPK, leading to the transcription of genes that govern immune responses, cell proliferation, and apoptosis. These immediate early responses are crucial for initiating and sustaining immune reactions but also pave the way for long-term changes through epigenetic modifications.

Epigenetic modifications, including DNA methylation, histone modifications, and the regulation of non-coding RNAs, provide an additional layer of gene expression control that is heritable and reversible. Cytokines like TNF-α, IL-6, and IFN-γ can induce DNA methylation changes that either activate or silence gene expression. For example, hypermethylation of tumor suppressor genes by pro-inflammatory cytokines can promote oncogenesis, while demethylation can activate genes involved in immune responses. Similarly, histone modifications such as acetylation and methylation can modulate chromatin structure and gene accessibility, further influencing gene expression patterns in response to cytokine signaling.

The regulation of non-coding RNAs, particularly miRNAs and lncRNAs, by cytokines adds complexity to gene expression control. miRNAs can fine-tune the expression of target genes post-transcriptionally, with cytokines like IL-1β inducing miR-155 to modulate inflammatory responses. lncRNAs, on the other hand, can interact with chromatin remodelers and transcription factors to influence gene expression more broadly, highlighting their role in cytokine-mediated gene regulation.

The implications of cytokine-induced gene expression and epigenetic modifications are profound in disease contexts. In autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), aberrant cytokine signaling and subsequent epigenetic changes contribute to chronic inflammation and autoimmunity. For instance, elevated levels of TNF-α and IL-6 in RA can drive the hypermethylation of regulatory genes, perpetuating inflammation and joint destruction.

In cancer, cytokines within the tumor microenvironment can induce epigenetic modifications that support tumor growth and metastasis. IL-6 and IL-8, for instance, can lead to the silencing of tumor suppressor genes and the activation of oncogenes through DNA methylation and histone modifications. Furthermore, cytokine-induced epigenetic changes can contribute to therapeutic resistance, posing challenges in cancer treatment.

Chronic inflammatory diseases like inflammatory bowel disease (IBD) and asthma also demonstrate the impact of cytokine-induced epigenetic modifications. In IBD, cytokines such as TNF-α and IL-1β drive inflammation and tissue damage through changes in gene expression and chromatin structure. In asthma, cytokine signaling results in epigenetic changes that lead to airway hyperresponsiveness and persistent inflammation.

The therapeutic potential of targeting cytokine signaling and epigenetic modifications is significant. JAK inhibitors and cytokine antagonists can modulate cytokine signaling pathways, offering relief in autoimmune and inflammatory conditions. Epigenetic therapies, including DNA methylation inhibitors and histone deacetylase inhibitors, can reverse aberrant epigenetic modifications, providing new avenues for cancer treatment. Additionally, RNA-based therapies targeting miRNAs and lncRNAs hold promise for fine-tuning gene expression in disease contexts.

Conclusion

The intricate interplay between cytokine signaling and gene expression regulation is a cornerstone of immune response modulation and has profound implications for disease pathogenesis and therapy. Cytokines, through pathways like JAK-STAT and MAPK, initiate and sustain immune responses by inducing specific gene expression patterns. These immediate responses are vital for effective immune function but also lead to longer-term changes through epigenetic modifications, which add another dimension to gene regulation.

Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, are crucial for maintaining cellular memory and adaptability. Cytokines such as TNF-α, IL-6, and IFN-γ influence these modifications, resulting in either the activation or silencing of genes. This dual capability underscores the complexity and significance of cytokine-induced epigenetic changes in various diseases.

Autoimmune diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) exemplify how cytokine-induced epigenetic modifications contribute to chronic inflammation and immune dysregulation. Elevated cytokine levels drive harmful epigenetic changes that perpetuate disease processes, highlighting the need for targeted interventions. In cancer, the tumor microenvironment, rich in cytokines, induces epigenetic alterations that promote tumorigenesis and metastasis while also contributing to therapeutic resistance. This underscores the necessity for epigenetic therapies alongside conventional treatments.

Chronic inflammatory diseases, including inflammatory bowel disease (IBD) and asthma, further illustrate the impact of cytokine-induced epigenetic modifications. In IBD, cytokine-driven changes in gene expression and chromatin structure lead to persistent inflammation and tissue damage. Similarly, in asthma, cytokine signaling results in epigenetic changes that drive airway hyperresponsiveness and chronic inflammation.

Therapeutic strategies targeting cytokine signaling and epigenetic modifications hold significant promise. JAK inhibitors and cytokine antagonists can modulate cytokine pathways, providing relief in autoimmune and inflammatory diseases. Epigenetic therapies, such as DNA methylation inhibitors and histone deacetylase inhibitors, can reverse aberrant epigenetic modifications, offering new hope for cancer treatment. RNA-based therapies targeting miRNAs and lncRNAs present innovative approaches for fine-tuning gene expression in various diseases.

Understanding the mechanisms by which cytokines induce gene expression and epigenetic modifications is crucial for developing these targeted therapies. The potential to modulate these molecular processes opens new avenues for treating complex diseases, emphasizing the need for continued research in this field. As our knowledge expands, so too will our ability to develop sophisticated treatments that address the root causes of these diseases, ultimately improving patient outcomes.

In summary, the study of cytokine-induced gene expression and epigenetic modifications provides critical insights into disease mechanisms and therapeutic opportunities. By harnessing this knowledge, we can develop innovative treatments that target the molecular underpinnings of autoimmune disorders, cancers, and chronic inflammatory diseases, paving the way for more effective and personalized medicine.

1. Van den Elsen LW, Poyntz HC, Weyrich LS, Young W, Forbes-Blom EE (2017) Embracing the gut microbiota: The new frontier for inflammatory and infectious diseases. Clin Transl Immunol 6:125

Indexed at, Google Scholar, Crossref

2. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, et al. (2017) Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 17: 909-948

Indexed at, Google Scholar, Crossref

3. Iacob S, Iacob DG, Luminos LM (2018) Intestinal Microbiota as a Host Defense Mechanism to Infectious Threats. Front Microbiol 9: 33-28

Indexed at, Google Scholar, Crossref

4. Lazar V, Ditu L-M, Pircalabioru GG, Gheorghe I, Curutiu C, et al. (2018) Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer. Front Immunol 9:1830

Indexed at, Google Scholar, Crossref

5. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, et al. (2009) Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325: 617-620

Indexed at, Google Scholar, Crossref

6. Vineis P, Robinson O, Chadeau-Hyam M, Dehghan A, Mudway I, et al. (2020) What is new in the exposome?. Environ Int 143:105887

Indexed at, Google Scholar, Crossref

7. Libertucci J, Young VB (2019) The role of the microbiota in infectious diseases. Nat Microbiol 4:35-45

Indexed at, Google Scholar, Crossref

8. Lawley TD, Walker AW (2013) Intestinal colonization resistance. Immunology 138:1-11

Indexed at, Google Scholar, Crossref

9. Chiu L, Bazin T, Truchetet M-E, Schaeverbeke T, Delhaes L et al. (2017) Protective Microbiota: From Localized to Long-Reaching Co-Immunity. Front Immunol 8:1678

Indexed at, Google Scholar, Crossref

10. Thompson JA, Oliveira RA, Xavier KB (2016) Chemical conversations in the gut microbiota. Gut Microbes 7: 163-170

Indexed at, Google Scholar, Crossref